BOSTON, Oct. 19 /PRNewswire/ -- There is increasing evidence that, with best intent, current biological technology cannot supply the world's six billion humans, and animal populations, with vaccines against emerging diseases at a rate that can contend with a disease's rapid appearance and change, e.g., before the disease has come and gone. In view of Replikins Ltd.'s demonstration that Replikins(TM) chemically synthesized vaccines produced in seven days can be effective, the company today proposed these new vaccines as a solution to the problem of these emerging diseases. Furthermore, it established WorldVaccines(TM), Ltd to test and distribute synthetic Replikins(TM) vaccines.
As the first batches of the biological H1N1 ("Swine Flu") vaccines reach consumers worldwide, seven months after the flu outbreak, this small biotech firm in Boston today announced that it has created the first truly synthetic influenza vaccine that targets the broad range of A influenza viruses including H1N1, H5N1, H9N2, and H3N2, which was shown to be effective against the H5N1 (Avian Flu) virus. TransFlu(TM) is the first truly synthetic cross-strain pan-influenza vaccine.
In an independent study published in the peer-reviewed journal Avian Diseases, the synthetic Replikins TransFlu(TM) vaccine was shown to be effective in decreasing infectivity and completely blocking excretion of LPAI H5N1 virus in chickens, permitting for the first time the possibility of blocking animal virus reservoir development, a major precursor of human disease.
Both TransFlu(TM) and Taura Syndrome Virus vaccines were manufactured in seven days; kilogram amounts could be made in a few weeks, rather than six to 12 months needed for biological vaccine production. The cost to produce the synthetic vaccine is also far less than the cost of current biological production methods. Given the demonstrated effectiveness and rapid availability, it appears inevitable that synthetic
|SOURCE Replikins Ltd.|
Copyright©2009 PR Newswire.
All rights reserved